Live prices paused — reconnecting…
Neuralink expands FDA human trials?
Loading...
Market trust
Review trustProviderManual ReviewEvidenceNot ReadyManual source - last checked Not checked yet
Market trust
Review trustProviderManual ReviewEvidenceNot ReadyManual source - last checked Not checked yet
- Trust score
- In review
- Source type
- Manual
- Provider health
- Manual Review
- Criteria quality
- Warn
- Market data quality
- Review
- Public evidence state
- Not Ready
- Chart data provenance
- Drazill Market Data
- Price history freshness
- Fresh
- Last source check
- Not checked yet
Trust methodology
Formula: market-trust-v1.0
Window: Latest market, criteria, provider, and evidence records
Confidence: MEDIUM
Informational only, not trading advice.
- - Provider health is market-specific when resolution checks exist and otherwise inferred from configuration.
- - Manual-only markets rely on admin review rather than automated source polling.
56%
Yes
@ $0.56
44%
No
@ $0.44
Market open
May 11, 2026, 06:41 p.m.
Market closes
Feb 24, 2027, 06:41 p.m.
Projected payout
After market closes
About This Market
Clinical trial expansion by end of 2026. Resolves YES if the FDA grants Neuralink approval to expand human clinical trials beyond the initial cohort before Jan 1, 2027. Source: FDA and Neuralink announcements
Source
Official announcement or authoritative source
